236 related articles for article (PubMed ID: 30867256)
1. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer.
Huang Y; Lou XY; Zhu YX; Wang YC; Zhang L; Liu HL; Wang C; Zhan HM; Cheng ZQ; Tan WY; Wang L; Fan XJ
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30867256
[TBL] [Abstract][Full Text] [Related]
2. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
[TBL] [Abstract][Full Text] [Related]
6. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Mohri Y; Kusunoki M
Anticancer Res; 2013 Nov; 33(11):5065-74. PubMed ID: 24222151
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
McCoy MJ; Hemmings C; Anyaegbu CC; Austin SJ; Lee-Pullen TF; Miller TJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
Oncotarget; 2017 Mar; 8(12):19803-19813. PubMed ID: 28177891
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of the Neutrophil-Lymphocyte Ratio for Tumor Regression Grade and Prognosis of Local Advanced Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
Li S; Wang D; Wei R; Yu G; Wang X; Jiang Z
Technol Cancer Res Treat; 2023; 22():15330338231202611. PubMed ID: 37807729
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
13. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
[TBL] [Abstract][Full Text] [Related]
14. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
[TBL] [Abstract][Full Text] [Related]
16. Density of CD8+ lymphocytes in biopsy samples combined with the circulating lymphocyte ratio predicts pathologic complete response to chemoradiotherapy for rectal cancer.
Xiao B; Peng J; Zhang R; Xu J; Wang Y; Fang Y; Lin J; Pan Z; Wu X
Cancer Manag Res; 2017; 9():701-708. PubMed ID: 29225479
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of combining the CD8 + lymphocyte density and the circulating lymphocyte ratio in circumferential resection margin biopsy in rectal cancer.
Wu B; Zhao S; Sheng Y; Ren L; Song G
Medicine (Baltimore); 2018 Aug; 97(34):e11972. PubMed ID: 30142826
[TBL] [Abstract][Full Text] [Related]
18. Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Sawada R; Akiyoshi T; Kitagawa Y; Hiyoshi Y; Mukai T; Nagasaki T; Yamaguchi T; Konishi T; Yamamoto N; Ueno M; Fukunaga Y
Ann Surg Oncol; 2021 Oct; 28(11):6189-6198. PubMed ID: 33876358
[TBL] [Abstract][Full Text] [Related]
19. Combined histopathological risk score using TP53 protein expression, CD8
Chen W; Farchoukh L; Seigh L; Hartman DJ; Pai RK
Histopathology; 2021 Nov; 79(5):826-835. PubMed ID: 34121230
[TBL] [Abstract][Full Text] [Related]
20. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
